Search results
Results from the WOW.Com Content Network
Cannabis use may be a contributory factor in the development of schizophrenia, potentially increasing the risk of the disease in those who are already at risk. [122] [123] [124] The increased risk may require the presence of certain genes within an individual. [22] Its use is associated with doubling the rate. [125]
Born: 1948 (age 76–77) Education: Miami University George Washington University (): Known for: Schizophrenia research NIMH CATIE study [1]: Children: 2: Awards: Lieber Prize for Schizophrenia Research from the National Association for Research in Schizophrenia and Affective Disorders
Aaron Beck was University Professor Emeritus of Psychiatry at the time of his death University of Pennsylvania and had continued doing research there, [7] while Judith Beck is a Clinical Professor of Psychology in Psychiatry at the same university. Lisa Coriano is Beck Institute's Executive Director, and Dr. Allen R. Miller is CBT Program Director.
The U.S. Food and Drug Administration (FDA) on Friday approved a new drug used for treating schizophrenia in adults, according to a press release. “This drug takes the first new approach to ...
The scientific principles which Dr. Noyes incorporated into his work are carried over through the Arthur Noyes Forensic Center (Building #51), the Arthur P. Noyes Schizophrenia Conference [25] and the Arthur P. Noyes Research Foundation. [26] To this day Dr. Noyes' portrait remains hung in the administration building in the hospital as a homage ...
The management of schizophrenia usually involves many aspects including psychological, pharmacological, social, educational, and employment-related interventions directed to recovery, and reducing the impact of schizophrenia on quality of life, social functioning, and longevity.
Roluperidone (former developmental code names MIN-101, CYR-101, MT-210) is a 5-HT 2A and σ 2 receptor antagonist under development by Minerva Neurosciences for the treatment of schizophrenia.
Coordinated Specialty Care (CSC) is a recovery-oriented treatment program designed for people with first episode psychosis (FEP). [1] CSC consists of collaborative treatment planning between the client and the client's care team, consisting of mental health clinicians, psychiatrists, and case managers.